Barclays initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot New Coverage New Coverage

Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Wedbush Amid Trial DesignMay 19, 2015 12:53 PM BofA/Merrill Lynch Downgrades Intercept (ICPT) to Neutral on Lack of CatalystsMay 19, 2015 11:51 AM Intercept (ICPT) NASH Study to be Larger, Riskier and Delayed, Leerink Partners SaysMay 19, 2015 11:51 AM BMO Capital Says Buy Intercept Pharmaceuticals (ICPT) on Weakness Related to Trial DesignMay 19, 2015 11:03 AM Intercept (ICPT) Bearish Concerns Tied to Trial Size; RBC Reiterates OutperformMay 19, 2015 9:24 AM Intercept's (ICPT) OCA Ph3 Trial Design or Size Not Seen as Surprise - Deutsche BankMay 19, 2015 8:36 AM Intercept Pharma (ICPT) Announces Design of OCA Phase 3 in NASH with Liver FibrosisMay 19, 2015 6:06 AM Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASHMay 19, 2015 6:00 AM